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Background: Dengue is the most common arboviral infection globally; a minority of
patients develop shock due to profound plasma leak through a disrupted endothelial
barrier. Understanding of the pathophysiology underlying plasma leak is incomplete, but
emerging evidence indicates a key role for degradation of the endothelial glycocalyx.
Methods: We conducted an observational study in Vietnam to evaluate the
sublingual microcirculation using sidestream darkfield imaging in (1) outpatients with
confirmed dengue (2) patients hospitalized with dengue and (3) outpatients with
other febrile illness (OFI). We estimated the glycocalyx degradation by measuring the
perfused boundary region (PBR hf) and an overall microvascular health score (MVHS)
with the software application GlycoCheckTM at enrolment, 48 h later and hospital
discharge/defervescence. We measured plasma syndecan1 and endocan at the same
time-points. We compared PBR hf, MVHS, syndecan1 and endocan, between (1)
outpatients with confirmed dengue vs. OFI and (2) patients with dengue subdivided by
clinical severity of plasma leak.
Results: We included 75 patients with dengue (41 outpatients, 15 inpatients, 19 in
intensive care) and 12 outpatients with OFI. Images from 45 patients were analyzed
using GlycoCheckTM. There was no significant difference in PBR hf or MVHS between
outpatients with dengue and OFI. Median plasma syndecan1 was not significantly
different in outpatients with dengue vs. OFI, while median plasma endocan was
significantly lower among patients with dengue vs. OFI during the critical phase. In
patients with dengue, PBR hf was higher in patients with Grade 2 vs. Grade 0
plasma leakage during the critical phase (PBR hf 1.96 vs. 1.36µm for Grade 2 vs.
Grade 0 plasma leakage on days 4–6, respectively, p < 0.001). Median levels of
plasma syndecan1 and endocan were higher in Grade 2 vs. Grade 0 plasma leakage,
especially during the critical phase (Syndecan1 2,613.8 vs. 125.9 ng/ml for Grade 2
vs. Grade 0 plasma leakage on days 4–6, respectively, p < 0.001, and endocan 3.21
vs. 0.16 ng/ml for Grade 2 vs. Grade 0 plasma leakage on days 4–6, respectively).
Lam et al. Glycocalyx Breakdown in Dengue
Conclusions: We present the first human in vivo evidence of glycocalyx disruption in
dengue, with worse visual glycocalyx damage and higher plasma degradation products
associated with more severe plasma leak.
Keywords: dengue, glycocalyx, microvascular, perfused boundary region, syndecan, endocan
INTRODUCTION
Dengue virus (DENV) infection is the most common arboviral
infection globally, with an estimated annual incidence of 96
million symptomatic infections (1). Although most infections
are self-limiting, a minority progress to shock due to profound
plasma leak through a disrupted endothelial barrier. The
endothelial hyper-permeability usually terminates abruptly after
∼48 h, with resorption of extravasated fluid into the intravascular
space. Although understanding of the mechanisms underlying
the onset and termination of plasma leak during dengue infection
remains incomplete, the endothelial glycocalyx is emerging as
central to the pathophysiology.
The endothelial glycocalyx is a negatively charged, ∼0.5–
5µm, layer lining the microvasculature. It comprises a mesh of
endothelial membrane-bound proteoglycans (such as syndecan-
1 and glypicans), glycoproteins (cell surface receptors such as
selectins and integrins), and glycosaminoglycans (GAGs - long,
negatively-charged linear polysaccharides including heparan
sulfate and chondroitin sulfate), with soluble plasma components
(including albumin, and thrombomodulin) embedded within (2).
The glycocalyx is a dynamic structure, whose components are
constantly shed and replenished during normal blood flow in
equilibrium with flowing macromolecules. It serves several key
roles including maintenance of barrier function, prevention of
leucocyte and platelet adhesion, modulation of clotting activation
and mechano-transduction of shear stress to regulate endothelial
nitric-oxide dependent vasodilation (2, 3).
Both in vivo and in vitro studies suggest that direct endothelial
damage can occur through DENV NS1 Ag and host-immune
mediated damage via TLR4 activation and vasoactive mediators,
contributing to the disruption of endothelial integrity (4–6). NS1
antigen is secreted fromDENV-infected cells into the circulation,
from where it attaches to chondroitin sulfate and heparan sulfate
(HS) (7). NS1 induces both cytokine-dependent and independent
damage to the endothelial glycocalyx, including direct induction
of endothelial heparanases (6). Previous clinical studies have
reported high plasma and urine levels of HS in dengue virus
infection (8, 9). However, it is not clear whether this elevation
is due to specific cleavage of HS from its core proteoglycan
syndecan-1 (SDC1), or whether there is more widespread
glycocalyx damage with shedding of core proteoglycans.
Laboratory-based research on the pathophysiology underlying
DENV induced glycocalyx disruption has predominantly been
performed using endothelial cell monolayers, with visualization
of the glycocalyx by transmission electron microscopy. However,
the glycocalyx readily degrades without the biomechanical forces
exerted by constant blood flow, and during dye/fixation processes
in the laboratory; thus, the potential to translate these methods
to study human microvascular pathophysiology during dengue
infection is limited.
We previously investigated the sublingual microcirculation
using videomicroscopy (side stream dark-field imaging, SDF)
during acute dengue infection and demonstrated that perfusion
and flow of the microcirculation is impaired proportionate
to disease severity (10). Technological advances now permit
assessment of glycocalyx damage by SDF. RBCs maintain a
measurable distance from the microvessel endothelial cells, and
this is thought to represent the endothelial glycocalyx layer;
the diameter of the glycocalyx is measured by subtracting the
diameter of the RBC column from the known internal diameter
of the vessel from SDF videos. The GlycoCheckTM system
measures how deeply RBC can penetrate into the glycocalyx layer,
which is reflected by the Perfused Boundary Region (PBR). A
high value means deeper penetration and more damage to the
glycocalyx. PBR hf is PBR estimated at fixed high flow level based
on flow-PBR curves for diameter classes 5–25 microns, which is
suggested to be a more accurate assessment of glycocalyx depth
than measurement in capillaries without flow.
As glycocalyx damage has not been assessed in dengue patients
before, we set out to re-analyze stored SDF images with the new
Glycocheck technology. We compared glycocalyx degradation
and biomarkers (SDC1 and endocan) between (1) patients
with DENV infection and other febrile illnesses (OFI), and (2)
patients with DENV infection with and without plasma leak.
We hypothesized that the glycocalyx degradation would be (1)
increased in patients with dengue vs. OFI and (2) increased
in dengue patients with vs. without plasma leakage. We also
hypothesized that PBR hf would correlate with plasma levels of
SDC1 and endocan.
METHODS
We used a selection of stored SDF videos and plasma samples
collected from patients recruited into an observational study on
vascular function in dengue between 2013 and 2015; the full
study protocol has been published elsewhere (10, 11). Briefly,
this was a prospective observational study of adults and children
>5 years presenting to two Vietnamese hospitals, the National
Hospital for Tropical Diseases (NHTD), Hanoi and the Hospital
for Tropical Diseases (HTD), Ho Chi Minh City. Two groups
of patients were recruited, either (1) individuals presenting
with a febrile illness consistent with dengue to outpatient
health facilities within 72 h of fever onset, or (2) individuals
hospitalized with dengue warning signs or severe dengue. At the
HTD site, only patients admitted to Intensive Care Unit (ICU)
were enrolled. Participants were followed daily until resolution
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FIGURE 1 | Study flowchart. A subset of patients prospectively enrolled into an observational study on vascular function in dengue between 2013 and 2015 had
Syndecan-1, endocan, and PBR hf measured. Except for one outpatient with dengue and two inpatients with dengue, all other patients with PBR hf also had
Syndecan-1 and endocan measured. NHTD, National Hospital for Tropical Diseases; HTD, Hospital for Tropical Diseases; ICU, Intensive Care Unit; OFI, Other Febrile
Illnesses; PBR hf, Perfused Boundary Region high flow.
of their acute illness. Hospital admission and individual case
management were determined according to clinical need, with
all interventions documented in the case report forms. Research
blood samples were obtained and microvascular assessments
including SDF imaging performed, at 4 time points: enrollment,
48 h later, hospital discharge/defervesence and follow-up between
days 14–21.
Ethical approval was obtained from the Oxford Tropical
Research Ethics Committee and the Ethics review Committee at
NHTD and HTD. Written informed consent was obtained from
all participants, or a parent/guardian of children.
LABORATORY INVESTIGATIONS
Dengue Diagnostics
Reverse transcriptase PCR (RT-PCR) (12), an NS1 test (Platelia
enzyme-linked immunosorbent assay; BioRad), and commercial
IgM serology assays (Capture ELISA, Panbio) were used to
confirm DENV infection. Patients were defined as having
laboratory confirmed dengue if RT-PCR, NS1 antigen or DENV
IgM assays were positive at enrolment, or if there was IgM
seroconversion between paired serological samples at least 5 days
apart. A diagnosis of OFI was assigned to outpatients with fever
but no laboratory evidence of acute or recent dengue—i.e., if




SDF videomicroscopy was performed by 3 investigators at the
4 time-points described above. Video clips were obtained at 3
different sublingual sites for 60 s, with attention to minimize
pressure artifacts and reduce secretions. Images were acquired
using a handheld videomicroscope with a x5 objective lens
(MicroVision Medical, Amsterdam, Netherlands), which uses
green light-emitting diode illumination at a wavelength (55 nm)
that is absorbed by hemoglobin in the red blood cells (RBCs). The
original video analysis was performed using AVA 3.2 software.
Due to a requirement for high quality images, only SDF
videomicroscopy clips of sufficient quality were forwarded for
GlycoCheck analysis (Figure 1); these video clips were analyzed
by technicians blinded to diagnosis, disease severity and time-
point at the Cardiovascular Research Institute of Maastricht
University (CARIM), Netherlands. In addition to measurement
of PBR hf, an overall microvascular assessment was made
using the MicroVascular Health Score (MVHS). MVHS is
derived using the PBR hf plus parameters representing the
RBC filling (RBCF, red cell content of blood vessels), and
valid vessel density (the subset of vessels that are functionally
relevant, i.e., those with sufficient number of red cells for
tissue perfusion). Lower values of MVHS reflect an overall
worse microvascular health and higher PBR hf reflect a more
degraded glycocalyx.
Glycocalyx Biomarker Measurements
At the same 4 time-points, plasma levels of SDC1 and endocan
were measured in patients whose images were forwarded
for Glycocheck analysis, and additional patients from both
NHTD and HTD sites with sufficient stored plasma (Figure 1).
Measurements were made using specific sandwich ELISAs for
SDC1 (Diaclone, Basancon, France) and endocan (Lunginnov,
Lille, France) according to the manufacturers’ instructions.
CLINICAL END-POINT DEFINITIONS
Different clinical outcomes of patients with DENV infection
could be defined based on World Health Organization’s
guidelines (13–15). However, we focused on plasma
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BOX 1 | Plasma leakage grades in dengue virus infection.
Grade 0 Grade 1 Grade 2
No clinically significant plasma leak: Moderate plasma leakage: Severe plasma leakage:
1 HCT <15% 1HCT 15–20% 1HCT > 20%
AND AND/OR AND/OR
No sign of fluid accumulation on clinical
examination or x-ray/ultrasound
Any sign of fluid accumulation on clinical
examination or x-ray/ultrasound
Shock or pleural effusion with respiratory
compromise
TABLE 1 | Characteristics at enrolment and clinical outcomes of patients included in this analysis.
OFI (n = 12) Dengue (n = 75)
Outpatient (n = 41) Inpatient (n = 15) ICU (n = 19)
Characteristics n Summary n Summary n Summary n Summary
At enrolment
Age (years) 12 24 (22, 28) 41 26 (22, 35) 15 26 (19, 36) 19 10 (7, 13)
Gender: female 12 6 (50) 41 20 (49) 15 9 (60) 19 9 (47)
Day of illness 12 41 15 19
1–3 11 (92) 32 (78) 2 (13) 1 (5)
4–6 1 (8) 9 (22) 10 (67) 16 (84)
7–8 0 (0) 0 (0) 3 (20) 2 (11)
PCR positive 12 0 (0) 41 37 (90) 15 9 (60) 19 13 (68)
Platelet count (109/L) 12 168 (147, 195) 39 144 (118, 176) 15 45 (29, 83) 18 26 (19, 34)
White blood cell count (109/L) 12 10.3 (5.2, 12.5) 39 4.2 (3.0, 5.0) 15 4.6 (3.1, 6.2) 18 4.5 (2.8, 5.2)
Albumin (g/L) 12 44 (41, 46) 36 46 (42, 48) 6 32 (26, 36) 18 33 (28, 37)
Aspartate aminotransferase (IU/L) 12 16 (15, 29) 39 32 (26, 50) 9 128 (71, 163) 18 172 (126, 483)
Alanine aminotransferase (IU/L) 12 12 (10, 22) 40 24 (16, 43) 9 77 (34, 87) 18 102 (41, 342)
Creatinine (µmol/L) 12 93 (77, 107) 39 83 (73, 114) 10 72 (62, 89) 16 51 (46, 56)
Outcome
WHO 2009 classification – 41 15 19
Dengue – 26 (63) 1 (7) 0 (0)
Dengue with warning signs – 12 (29) 8 (53) 3 (16)
Severe dengue – 3 (7) 6 (40) 16 (84)
Plasma leakage grade – 41 14 18
Grade 0 – 33 (80) 6 (43) 1 (6)
Grade 1 – 6 (15) 2 (14) 1 (6)
Grade 2 – 2 (5) 6 (43) 16 (88)
Haemoconcentration >20% – 41 2 (5) 12 3 (25) 16 11 (69)
Pleural effusion with respiratory compromise – 41 0 (0) 15 3 (20) 19 5 (26)
Dengue shock syndrome – 41 1 (2) 15 2 (13) 19 16 (84)
Summary statistic is absolute count (%) for categorical variables and median (IQR) for continuous variables.
Haemoconcentration percentage was defined as (peak haematocrit—baseline haematocrit/baseline haematocrit) x100, “peak haematocrit” was the maximum of at least 3 haematocrit
values in the acute illness (at least one of them was between days 4–7), and “baseline haematocrit” was the lowest value (in the following order) from the follow-up sample, a sample
obtained within 72 h of fever onset, or (for hospitalized patients only) the discharge sample, provided no parenteral fluid was administered during the preceding 12 h.
OFI, Other Febrile Illnesses; ICU, Intensive Care Unit; PCR, Polymerase Chain Reaction.
leakage in this study. Patients with DENV infection were
subdivided by plasma leakage grade as shown in Box 1. The
haemoconcentration percentage [1 Haematocrit (HCT)] was
defined as (peak – baseline HCT/baseline HCT) x100. Clinical
examination and chest X ray and/or ultrasound of the lungs
and abdomen were performed to assess for extravascular
fluid accumulation.
STATISTICAL ANALYSIS
First, the PBR hf, MVHS and glycocalyx biomarkers were
compared between outpatients with confirmed dengue vs. OFI.
Subsequently, the PBR hf, MVHS and glycocalyx biomarkers
were compared between patients with dengue with varying
degrees of plasma leakage using the mean difference between
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groups as the effect measure. As distributions of SDC1 and
endocan are right-skewed, they were log-transformed prior to
comparison. All analyses were based on linear regression models
with the PBR hf and glycocalyx biomarkers as the outcome of
interest, and dengue diagnosis or plasma leakage as covariates.
For each covariate, an initial comparison with the outcome of
interest used all measurements from the various time points
assessed excluding the follow up values; separate analyses were
subsequently performed for each disease phase: early (illness day
1–3); critical (illness day 4–6); recovery (illness day 7–13) and
follow-up (after 13 days). Because most patients had multiple
microcirculatory measurements performed, potentially with >1
measurement within each disease phase, robust sandwich errors
based on working independence covariance structure derived
from generalized estimating equations were used throughout the
study. Comparisons were adjusted for age, sex, and illness day
as appropriate. Of note, about half of the endocan values were
below the limit of detection; therefore we conducted sensitivity
analyses in which we imputed them using different values and
investigated the impact on results. As results for endocan were
consistent across scenarios in the sensitivity analysis, only the
most conservative scenario (imputing below detection limit
values with the detection limit of 0.156 ng/mL) is presented in
the main results section. The full sensitivity analysis is reported
in the Appendix.
Associations between PBR hf, MVHS and glycocalyx
biomarkers in patients with dengue were assessed by means
of partial correlations, controlling for the following potential
confounding variables: age, sex, and illness day at measurement.
The significance of partial correlations was assessed based
TABLE 2 | Glycocalyx parameters for outpatients with dengue and OFI by disease phase.
OFI (n = 12) Dengue (n = 41)
Time-point n N Median (IQR) n N Median (IQR) MD (95% CI) p-value
Glycocalyx videomicroscopy assessment
PBR hf
Overall 8 14 1.23 (1.18, 1.36) 26 65 1.39 (1.20, 1.61) 0.10 (−0.07, 0.28) 0.260
Days 1–3 7 8 1.23 (1.18, 1.33) 17 26 1.38 (1.20, 1.58) 0.10 (−0.05, 0.26) 0.197
Days 4–6 5 6 1.23 (1.17, 1.39) 19 28 1.42 (1.23, 1.63) 0.13 (−0.13, 0.39) 0.320
Days 7–13 0 0 – 11 11 1.20 (1.14, 1.54) – – –
Days >13 4 4 1.35 (1.29, 1.39) 7 7 1.35 (1.21, 1.39) −0.02 (−0.10, 0.07) 0.708
MVHS
Overall 8 14 1.94 (1.80, 2.66) 26 65 1.95 (1.42, 2.60) −0.10 (−0.62, 0.43) 0.714
Days 1–3 7 8 1.94 (1.88, 2.55) 17 26 1.82 (1.31, 2.42) −0.19 (−0.64, 0.27) 0.415
Days 4–6 5 6 2.12 (1.78, 2.78) 19 28 2.04 (1.40, 2.77) 0.00 (−0.75, 0.75) 0.999
Days 7–13 0 0 – 11 11 2.29 (1.83, 2.75) – – –
Days >13 4 4 2.14 (1.83, 2.33) 7 7 2.40 (2.05, 3.12) 0.65 (0.17, 1.13) 0.008
Glycocalyx biomarker measurements
SDC1
Overall 11 31 25.7 (8.1, 46.3) 40 113 80.9 (34.7, 206.9) 3.33 (0.95, 5.72) 0.006
Days 1–3 10 14 26.4 (6.6, 53.7) 32 44 45.9 (33.2, 127.1) 3.52 (−0.22, 7.26) 0.065
Days 4–6 10 15 25.7 (8.6, 36.1) 34 54 119.2 (45.0, 208.6) 3.09 (0.33, 5.85) 0.028
Days 7–13 2 2 45.1 (33.6, 56.7) 14 15 1,021.8 (91.52, 1,434.0) – – –
Days >13 6 6 12.7 (9.5, 27.9) 20 20 22.2 (14.2, 46.9) −0.18 (−1.95, 1.59) 0.840
Endocan
Overall 12 34 0.97 (0.16, 2.44) 37 107 0.16 (0.16, 1.35) −1.20 (−2.05,−0.35) 0.006
Days 1–3 11 16 0.35 (0.16, 2.39) 29 40 0.16 (0.16, 0.83) −0.79 (−1.95, 0.38) 0.186
Days 4–6 11 16 1.49 (0.21, 2.55) 31 50 0.16 (0.16, 0.61) −1.55 (−2.57,−0.54) 0.003
Days 7–13 2 2 2.22 (1.65, 2.78) 16 17 2.30 (0.62, 3.23) – – –
Days >13 7 7 0.19 (0.16, 0.40) 18 18 0.16 (0.16, 0.97) 0.18 (−0.84, 1.19) 0.733
Since patients could contribute more than one measurement within and between groups, n, number of patients, and N, number of measurements in each group. Units are ng/ml
for SDC1 and endocan, µm for PBR hf. The MDs represent mean differences in the corresponding biomarker between patients with dengue and OFI. For SDC1 and endocan, MDs
represent mean differences in natural logarithm of SDC1 and endocan between patients with dengue and OFI.
“Overall” includes all values except for follow-up values, adjusted for age, sex and illness day. Other rows present comparisons for each disease phase, with adjustment for age and sex.
All comparisons were based on linear regression model using generalized estimating equations with independence covariance structure to take into account multiple measurements
per patient. Values that cannot be reliably estimated due to low number of measurements were indicated as –.
Values below the limit of detection for Endocan were imputed as 0.156 ng/mL (detection limit) in this analysis.
SDC1, Syndecan-1; CI, Confidence Interval; PBR hf, Perfused Boundary Region high flow; MVHS, MicroVascular Health Score; OFI, Other Febrile Illness; MD, Mean Difference; IQR,
InterQuartile Range.
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FIGURE 2 | Boxplot of perfused boundary region and microvascular health score by disease phase in patients with dengue versus OFI. The short black line indicates
the median value in each disease phase. The graph is based on 34 outpatients (26 dengue and 8 OFI) contributing 79 measurements. The numbers at the bottom of
the graph indicate the number of patients in each group. PBR hf, Perfused Boundary Region high flow; MVHS, MicroVascular Health Score; OFI, Other Febrile Illness.
FIGURE 3 | Boxplot of PBR hf and MVHS by plasma leakage grade and disease phase for patients with laboratory confirmed dengue. Dots represent individual
values of PBR hf and MVHS in each group. The number represents the number of patients that contributed to each group. The graph is based on 36 patients
contributing 87 measurements. PBR hf, Perfused Boundary Region high flow; MVHS, MicroVascular Health Score.
on their Fisher transformation and corresponding bootstrap
standard errors. The cluster bootstrap, which resamples patients
rather than individual parameter values, accounted for multiple
measurements per patient. To adjust for multiplicity informally,
we used a significance level of 0.01 for all comparisons.
All analyses were performed with the statistical software R




A total of 75 patients with dengue (41 recruited from outpatients,
15 inpatients, 19 in ICU) and 12 outpatients with OFI were
included in this analysis (Table 1). High quality images from
45 of these patients (8 = with OFI and n = 37 with dengue
with a range of plasma leak) were forwarded for the analysis
of PBR hf. Figure 1 shows the number of patients included in
each analysis.
Glycocalyx Videomicroscopy Assessment
There were no statistically significant differences in PBR
hf or MVHS (or of its components RBC filling, Valid
vessel Density) between the dengue and OFI groups in
pooled or illness day specific analyses (Table 2, lower
panel, Figure 2). Collectively, these data indicate similar
patterns of glycocalyx disturbance in the outpatient
dengue and OFI patient groups. Of note, only two of
the outpatients with dengue included in this analysis
subsequently progressed to require hospitalization with Grade 2
plasma leakage.
PBR hf values were obtained for a selection of 36 outpatients
and inpatients with dengue at NHTD (Figure 3, Table 3, lower
panel). Pooling all values up to illness day 13, the PBR hf
value was higher in patients with Grade 2 vs. Grade 0 plasma
leakage, which was driven by a marked difference in PBR hf
during the critical phase [PBR hf 1.96 vs. 1.36µm for Grade
2 vs. Grade 0 plasma leakage on days 4–6, respectively, mean
difference 0.43µm (95%CI 0.25–0.61) p < 0.001]. There were
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no statistically significant differences between patients with other
plasma leakage grades in other illness day categories. There
were insufficient measurements taken at follow-up to permit
meaningful comparison by plasma leakage grade. For MVHS,
pooled analysis suggests a significantly lower score in patients
with Grade 2 compared to patients with Grade 0 plasma leak
[mean difference of −0.53 (95%CI −0.82, −0.25), p < 0.001],
as well as reductions in its other components, including RBCF
[75.1 vs. 68.8%, mean difference of −2.82 (95% CI −5.6 to
0.03, p = 0.047), and valid density (273 vs. 173 sites/mm2,
mean difference of −62.0 (95%CI −106.6, −17.5), p = 0.006].
However, there was no clear indication of a difference by illness
day group.
We did not find significant partial correlations (using P
< 0.01) between the levels of core proteoglycans SDC1 and
endocan, and the microcirculatory parameters PBR hf and
MVHS, after controlling for age, sex and illness phase (Figure 4).
The correlation of PBR hf and SDC1 approached significance
with p= 0.032.
Glycocalyx Biomarker Measurements
Median plasma SDC1was higher among outpatients with dengue
compared to OFI at all time-points, but after adjustment for
multiple comparisons, the differences did not reach statistical
significance (Table 2, upper panel). In contrast, median plasma
endocan was significantly lower among patients with dengue
compared to OFI during the critical phase (illness day 4–6).
Results for patients with laboratory confirmed dengue
categorized by plasma leakage severity are presented in Table 3,
upper panel. Median plasma SDC1 levels were higher in patients
with Grade 2 plasma leakage compared to Grade 0 plasma leakage
at all time-points, the difference being most marked during the
critical phase (SDC1 2,613.8 vs. 125.9 ng/ml for Grade 2 vs. Grade
0 plasma leakage on day 4–6, p < 0.001). Similarly, median
plasma endocan levels were higher in patients with Grade 2
plasma leakage compared to Grade 0 plasma leakage at all time-
points, especially during the critical phase (Endocan 3.21 vs.
0.16 ng/ml for Grade 2 vs. Grade 0 plasma leakage on day 4–6, p=
0.003) and recovery phase (Endocan 5.38 vs. 2.38 ng/ml for Grade
FIGURE 4 | Scatterplot and partial correlation coefficient (Rho) between the respective two parameters of interest controlling for age, sex, and day of illness at
measurement. The significance of partial correlations (p) was assessed based on their Fisher transformation and corresponding bootstrap standard errors. Values
below the limit of detection for Endocan were imputed as 0.156 ng/mL (detection limit) in this analysis.




























TABLE 3 | Glycocalyx parameters for outpatient and inpatients with laboratory confirmed dengue by plasma leakage grade and disease phase.
Leakage grade 0 Leakage grade 1 Leakage grade 2 Leakage grade 1 vs. 0 Leakage grade 2 vs. 0
Time-
point
N N Median (IQR) n N Median (IQR) n N Median (IQR) MD (95% CI) p-value MD (95% CI) p-value
Glycocalyx videomicroscopy assessment
PBR hf
Overall 24 60 1.38 (1.20, 1.57) 5 12 1.39 (1.21, 1.55) 7 15 1.76 (1.58, 1.98) 0.04 (−0.08, 0.16) 0.502 0.20 (0.04, 0.36) 0.013
Days 1–3 14 21 1.38 (1.21, 1.57) 3 5 1.45 (1.21, 1.54) 2 3 1.02 (0.99, 1.39) 0.04 (−0.14, 0.23) 0.640 −0.12 (−0.48, 0.23) 0.501
Days 4–6 19 29 1.36 (1.22, 1.57) 4 5 1.48 (1.33, 1.58) 3 4 1.96 (1.90, 1.98) 0.10 (−0.15, 0.35) 0.424 0.43 (0.25, 0.61) <0.001
Days
7–13
10 10 1.44 (1.17, 1.56) 2 2 1.14 (1.07, 1.20) 6 8 1.68 (1.59, 1.97) −0.15 (−0.39, 0.08) 0.205 0.24 (−0.02, 0.51) 0.069
Days
>13
7 7 1.35 (1.21, 1.39) 0 0 – 4 4 1.53 (1.32, 1.67) – – – – – –
MVHS
Overall 24 60 2.08 (1.44, 2.75) 5 12 2.14 (1.59, 2.69) 7 15 1.40 (1.11, 1.97) 0.08 (−0.26, 0.42) 0.630 −0.55 (−0.85, −0.26) <0.001
Days 1–3 14 21 1.88 (1.28, 2.57) 3 5 2.02 (1.61, 2.26) 2 3 1.66 (1.40, 2.04) 0.03 (−0.47, 0.54) 0.892 −0.30 (−1.40, 0.80) 0.589
Days 4–6 19 29 2.16 (1.44, 2.78) 4 5 1.56 (1.20, 2.77) 3 4 1.07 (0.69, 1.57) −0.20 (−1.06, 0.66) 0.656 −0.84 (−1.62, −0.06) 0.034
Days
7–13
10 10 2.12 (1.75, 2.77) 2 2 3.01 (2.79, 3.23) 6 8 1.32 (1.19, 1.97) 0.68 (−0.45, 1.81) 0.236 −0.61 (−1.11, −0.10) 0.018
Days
>13
7 7 2.62 (2.30, 3.12) 0 0 – 4 4 1.80 (1.58, 1.98) – – – – – –
Glycocalyx biomarker measurements
SDC1
Overall 38 111 124.8 (41.6, 281.1) 8 25 212.9 (26.4, 450.3) 24 73 1,220.1 (268.5, 3,149.9) −0.29 (−2.49, 1.91) 0.796 2.67 (1.16, 4.17) <0.001
Days 1–3 25 33 46.9 (36.4, 134.0) 6 10 30.6 (23.2, 43.8) 3 4 117.0 (66.5, 484.2) −0.85 (−1.80, 0.11) 0.082 0.87 (−1.79, 3.53) 0.523
Days 4–6 34 56 125.9 (47.7, 220.3) 6 9 228.6 (212.9, 450.3) 20 34 2,613.8 (1,182.7, 3,910.9) −0.71 (−5.22, 3.80) 0.757 3.76 (1.61, 5.91) <0.001
Days
7–13
14 22 678.2 (139.4, 1,136.9) 5 6 990.81 (422.69, 1,583.94) 23 35 668.5 (181.3, 1,803.3) 1.20 (−1.11, 3.51) 0.310 1.67 (−0.13, 3.47) 0.070
Days
>13
19 19 20.5 (13.2, 49.8) 3 3 63.30 (41.10, 140.44) 20 20 34.43 (12.63, 90.10) 0.98 (−0.50, 2.46) 0.193 3.69 (0.37, 7.00) 0.029
Endocan
Overall 34 100 0.16 (0.16, 2.27) 7 22 0.58 (0.16, 6.28) 16 47 4.00 (0.85, 7.75) 1.09 (−0.03, 2.20) 0.056 1.68 (0.69, 2.66) <0.001
Days 1–3 22 29 0.16 (0.16, 1.39) 6 10 0.16 (0.16, 0.16) 3 4 0.48 (0.16, 1.60) −0.72 (−1.82, 0.38) 0.200 1.30 (−1.20, 3.80) 0.307
Days 4–6 30 51 0.16 (0.16, 1.07) 5 7 3.91 (1.37, 6.85) 13 21 3.21 (0.82, 7.84) 2.40 (1.07, 3.72) <0.001 2.14 (0.73, 3.55) 0.003
Days
7–13
15 20 2.38 (0.70, 6.58) 4 5 7.12 (2.85, 12.60) 15 22 5.38 (2.55, 8.17) 1.94 (0.03, 3.86) 0.047 1.69 (0.48, 2.90) 0.006
Days
>13
17 17 0.20 (0.16, 1.14) 2 2 0.16 (0.16, 0.16) 13 13 0.91 (0.62, 1.55) −1.47 (−2.29, −0.65) <0.001 0.80 (−0.48, 2.07) 0.222
Since patients could contribute more than one measurement within and between groups, n, number of patients, and N, number of measurements in each group. Units are ng/ml for SDC1 and endocan, µm for PBR hf,. The mean
difference (MD) represents difference in plasma level/score between patients with plasma leakage grades (grade 1 compared to grade 0 and grade 2 compared to grade 0). For SDC1 and endocan, MDs represent mean differences in
natural logarithm of SDC1 and endocan between patient groups.
“Overall” includes all values except for follow-up values, adjusted for age, sex and day of illness. Other rows present comparisons for each disease phase, with adjustment for age and sex. All comparisons were based on linear regression
using generalized estimating equations with independence covariance structure to take into account multiple measurements per patient. Values cannot be reliably estimated due to low number of measurements were indicated as –.
Values below the limit of detection for Endocan were imputed as 0.156 ng/mL (detection limit) in this analysis.
For SDC1 and endocan, the analyses were based on 70 dengue patients (including 18 ICU patients); whereas for PBR hf and MVHS, the analyses were based on 36 dengue patients (not including any ICU patients).
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FIGURE 5 | Boxplot of plasma SDC1 and endocan measurements by illness day and plasma leakage grade for patients with laboratory confirmed dengue. Dots
represent individual values of SDC1 and endocan in each group. The number below represents the number of patients that contributed to each group. The SDC1
graph is based on 70 patients contributing 209 measurements, and the endocan graph is based on 57 patients contributing 169 measurements. Values below the
limit of detection for Endocan were imputed as 0.156 ng/mL (detection limit) in this analysis.
2 vs. Grade 0 plasma leakage on day 7–13, p = 0.006) (Figure 5,
Table 3).
DISCUSSION
In this observational study, we have shown that the glycocalyx
is significantly degraded in patients with the most severe clinical
manifestations of plasma leak due to dengue infection. In
addition, plasma levels of two glycocalyx core proteoglycans,
SDC1 and endocan, were elevated in association with clinical
severity of plasma leak. However, there were not significant
differences when comparing glycocalyx breakdown between
outpatients with dengue, most of whom had mild plasma leak,
and other non-severe febrile illnesses.
Suwarto et al. (18) also found an association between plasma
SDC1 levels and severity of plasma leak in adults with dengue
in Indonesia. However, median SDC1 level was higher among
patients with severe plasma leakage during the critical phase in
our study (median SDC1 2,613.8 ng/ml, IQR 1,182–3,910 ng/ml
in our study, vs. median 468.87 ng/ml, IQR 278.7–538.06 ng/ml
reported by Suwarto et al.), despite use of the same ELISA in both.
This difference might be explained by relatively earlier plasma
sampling by Suwarto et al., or by more severe disease among our
study participants.
SDC1 shedding has been demonstrated in other forms of
shock; patients admitted with haemorrhagic shock due to major
trauma had significantly raised SDC1 levels compared to healthy
controls (median 545 vs. 37 ng/ml) (19). Several studies have also
found SDC1 levels to be raised in proportion with sepsis severity,
as recently summarized by Uchimido et al. (20). Although our
control population did not include patients with other severe
febrile illnesses, the levels of SDC1 in patients with severe
plasma leakage in our study were several fold higher than in
most other published studies of shock (20); this may provide a
plausible explanation for why patients with dengue shock appear
to experience a more marked plasma leakage than those with
haemorrhagic and septic shock.
In this study, we found that plasma endocan levels were higher
during the critical phase in dengue with severe plasma leakage
vs. no plasma leakage. However, endocan levels reported in the
published literature for patients with septic shock appear to be
higher when compared to patients in our study with dengue
shock. Mihajlovic et al. reported endocan levels in patients with
septic shock [mean: 6.11 ± 7.8 ng/ml, n = 12 (21)], compared
to a median of 4.0 ng/ml in patients with dengue shock in
this study. Indeed, when comparing outpatients with dengue
vs. OFI over all time-points, we found that median endocan
levels were higher in patients with OFI compared to dengue.
This suggests that although endocan is elevated in proportion to
plasma leak severity, it may be a poorly specific biomarker for
dengue-induced glycocalyx breakdown.
A possible reason for targeted SDC1 shedding over endocan
could be related to dengue viral binding to heparan sulfate (HS),
SDC1’s GAG side chain. We have previously shown that patients
with dengue have higher levels of plasma and urinary HS (8).
The results from the current study suggest that DENV does not
cause isolated HS release into the circulation after viral binding,
but that more widespread damage to the glycocalyx occurs with
core proteoglycan release into the circulation in addition to
the GAG side chains (22). Viral or NS1 binding to HS may
result in enzymatic degradation of HS, with subsequent increase
in the susceptibility of SDC1 to proteolytic cleavage by matrix
metalloproteinases (MMP’s) (23). An alternative explanationmay
be leakage of shed endocan through the disrupted endothelial
barrier, leading to an artifactual lowering of plasma levels
compared to OFI in mild disease.
Taken together, our results suggest there is targeted
glycocalyx damage in dengue with severe plasma leakage,
with damage to core proteoglycans in addition to GAG
sidechains, and a simultaneous decrease in the depth of the
glycocalyx. Preservation of this layer by preventing shedding
of glycocalyx components, or accelerating repair may be a
potential therapeutic target (20). Although no therapeutic agents
to abrogate glycocalyx breakdown have yet been investigated
in humans with dengue, interest is growing in the potential
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to translate therapeutics developed for other indications;
these include strategies to inhibit heparanase activity [modified
heparins, Sulodexide (24)], downregulateMMP activity to reduce
proteoglycan shedding [S1P analogs (25, 26)], use intravenous
fluids (IV) which may accelerate glycocalyx repair (27) [albumin
(28), fresh frozen plasma (29)], or avoid bolus administration of
IV fluids to prevent further damage to a fragile glycocalyx (30).
However, screening of such therapeutic strategies for vascular
leak in dengue requires an improvement in vitro models to
evaluate glycocalyx integrity.
The extent to which the observed reduction in glycocalyx
depth in the sublingual microcirculation mirrors changes
in the glycocalyx in other microvascular beds is uncertain.
However, unlike other flaviviruses, dengue appears to cause
systemic, rather than organ-specific microvascular damage (31),
thus in dengue the sublingual changes may be an adequate
sentinel for glycocalyx degradation in other microvascular beds.
In this study, glycocalyx thickness was most diminished in
patients with severe plasma leak during the critical phase,
when plasma leak is already clinically apparent. Therefore,
the SDF technique might not be useful for early risk
prediction, but it may serve as an additional surrogate
to other clinical and biological endpoints to evaluate the
impact of novel therapeutic strategies on glycocalyx integrity
during future research (32). Utilizing software updates for the
glycocheck analysis allowing automated real-time evaluation of
the glycocalyx and future development of a point-of-care assays
for syndecan would provide clinically useful bedside tools for
assessment of microvascular damage and plasma leakage in
dengue patients.
A strength of this study is that the microcirculation was
evaluated early during the disease course, which allowed the
evolution and timing of the glycocalyx pathology to be studied.
In addition, studying the changes in vivo eliminated the problems
mentioned above with respect to in vitro models of glycocalyx
integrity. A limitation of this study is that our control population
did not include patients with other severe infections such as
septic shock; it is possible that the increase in PBR hf we
observed in patients with severe plasma leak is also non-specific.
Direct comparison of PBR hf with simultaneous, serial plasma
measurement of several glycocalyx components would help to
clarify whether the pathology is common to patients with other
forms of shock, or specific to dengue; the answers may aid
translation of therapeutic candidates.
In conclusion, we have shown visual and biochemical
evidence of glycocalyx degradation in patients with dengue virus
infection. Further, the most marked disruption was found in
patients with severe clinical manifestations of plasma leakage.
Exploring therapeutic strategies to prevent further damage to,
or accelerate restoration of the glycocalyx layer may help to
reduce morbidity associated with plasma leak in dengue; SDC1
and/or PBR hf may serve as useful surrogate endpoints in future
clinical trials.
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